Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Nkarta, Inc.NASDAQ: NKTX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $2.34M rose 1.8% year over year, ahead of the -5.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 21.1% from the prior quarter. Over 3 fiscal years it compounded at +20.5% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1.8% holds above the trailing-twelve-month pace of -5.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 4.61M USD
- Year-over-year change
- +105.9%
- 4-year CAGR
- +27.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.61M | +105.9% |
| FY2024 | 2024-12-31 | 2.24M | -61.8% |
| FY2023 | 2023-12-31 | 5.87M | +122.6% |
| FY2022 | 2022-12-31 | 2.64M | +50.2% |
| FY2021 | 2021-12-31 | 1.76M | — |
Depreciation & Amortization vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.0% is the 5th highest of 8, against a peer median of -2.3%.
- Over three fiscal years its annual growth of +20.5% compares with a peer median of +2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.71M USD | -33.0% | -12.3% | 185.5% | |
| LTM Mar 2026 | $8.78M USD | +4.6% | — | 47.7% | |
| LTM Mar 2026 | $8.74M USD | -5.0% | +20.5% | — | |
| LTM Mar 2026 | $3.2M USD | -5.6% | +118.5% | — | |
| LTM Mar 2026 | CHF 2.37M CHF | +2.1% | -3.5% | — | |
| LTM Mar 2026 | $2.09M USD | -38.1% | +4.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $1.14M USD | -2.3% | +2.2% | — |
| LTM Mar 2026 | $70K USD | +62.8% | — | — | |
| Peer median (excluding NKTX) | — | -2.3% | +2.2% | 116.6% | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 2.24M | 4.61M |
| Deferred Income Tax | 3.24M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.46M | 16.86M | 17.2M | 16.73M | 8.56M |
| Change in Working Capital | (1.64M) | 33.74M | 10.93M | (12.16M) | (435K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.79M | 2.76M | 4.22M | (4.47M) | 2.46M |
| Other Working Capital | (4.44M) | 30.98M | 6.7M | (7.69M) | (2.9M) |
| Other Non-Cash Items | 337K | 3.61M | (2.65M) | 2.29M | 2.65M |
| Operating Cash Flow | (67.93M) | (57M) | (86.16M) | (99.7M) | (88.7M) |
| Capital Expenditures | (5.03M) | (47.11M) | (28.15M) | (4.41M) | (1.21M) |
| Acquisitions (Net) | (37.56K) | 137.58K | 0 | 0 | 0 |
| Purchases of Investments | (227.28M) | (385.89M) | (260.23M) | (406.38M) | (238.57M) |
| Sales of Investments | 264.84M | 248.31M | 367.4M | 281.23M | 340.09M |
| Other Investing Activities | 37.56K | (137.58K) | 0 | 0 | 0 |
| Investing Cash Flow | 32.53M | (184.69M) | 79.02M | (129.56M) | 100.32M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.2M | 217.17M | 691K | 225.07M | 141K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.84M | 0 | 1.01M | 0 |
| Financing Cash Flow | 1.2M | 219.01M | 691K | 226.08M | 141K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (34.19M) | (22.68M) | (6.45M) | (3.17M) | 11.76M |
| Free Cash Flow | (72.95M) | (104.11M) | (114.31M) | (104.11M) | (89.91M) |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.